Clinical characteristics and p-AKT Ser473 expression status of patients with DLBCL
. | . | High p-AKT . | . | Low p-AKT . | . | . | ||
|---|---|---|---|---|---|---|---|---|
. | Total . | n . | % . | n . | % . | P . | ||
| No. of patients | 64 | 35 | 55 | 29 | 45 | |||
| Age, y | .279 | |||||||
| 60 or younger | 35 | 17 | 49 | 18 | 51 | |||
| Older than 60 | 29 | 18 | 62 | 11 | 38 | |||
| Sex | .330 | |||||||
| Female | 17 | 11 | 65 | 6 | 35 | |||
| Male | 47 | 24 | 51 | 23 | 49 | |||
| Performance status | .133 | |||||||
| Lower than 2 | 40 | 19 | 48 | 21 | 52 | |||
| 2 or higher | 24 | 16 | 67 | 8 | 33 | |||
| Stage | .225 | |||||||
| I or II | 30 | 14 | 47 | 16 | 53 | |||
| III or IV | 34 | 21 | 62 | 13 | 38 | |||
| Extranodal sites involved | .01 | |||||||
| 1 site | 40 | 17 | 43 | 23 | 57 | |||
| More than 1 site | 24 | 18 | 75 | 6 | 25 | |||
| LDH level* | .343 | |||||||
| Normal | 26 | 12 | 46 | 14 | 54 | |||
| High | 36 | 21 | 58 | 15 | 42 | |||
| IPI | .111 | |||||||
| Low to low-intermediate | 35 | 16 | 46 | 19 | 54 | |||
| High-intermediate to high | 29 | 19 | 66 | 10 | 34 | |||
| B symptoms | .003 | |||||||
| Absent | 29 | 10 | 35 | 19 | 65 | |||
| Present | 35 | 25 | 71 | 10 | 29 | |||
| Ki-67 expression (n = 95) | .009 | |||||||
| Positive | 83 | 46 | 55 | 37 | 45 | |||
| Negative | 12 | 2 | 17 | 10 | 83 | |||
. | . | High p-AKT . | . | Low p-AKT . | . | . | ||
|---|---|---|---|---|---|---|---|---|
. | Total . | n . | % . | n . | % . | P . | ||
| No. of patients | 64 | 35 | 55 | 29 | 45 | |||
| Age, y | .279 | |||||||
| 60 or younger | 35 | 17 | 49 | 18 | 51 | |||
| Older than 60 | 29 | 18 | 62 | 11 | 38 | |||
| Sex | .330 | |||||||
| Female | 17 | 11 | 65 | 6 | 35 | |||
| Male | 47 | 24 | 51 | 23 | 49 | |||
| Performance status | .133 | |||||||
| Lower than 2 | 40 | 19 | 48 | 21 | 52 | |||
| 2 or higher | 24 | 16 | 67 | 8 | 33 | |||
| Stage | .225 | |||||||
| I or II | 30 | 14 | 47 | 16 | 53 | |||
| III or IV | 34 | 21 | 62 | 13 | 38 | |||
| Extranodal sites involved | .01 | |||||||
| 1 site | 40 | 17 | 43 | 23 | 57 | |||
| More than 1 site | 24 | 18 | 75 | 6 | 25 | |||
| LDH level* | .343 | |||||||
| Normal | 26 | 12 | 46 | 14 | 54 | |||
| High | 36 | 21 | 58 | 15 | 42 | |||
| IPI | .111 | |||||||
| Low to low-intermediate | 35 | 16 | 46 | 19 | 54 | |||
| High-intermediate to high | 29 | 19 | 66 | 10 | 34 | |||
| B symptoms | .003 | |||||||
| Absent | 29 | 10 | 35 | 19 | 65 | |||
| Present | 35 | 25 | 71 | 10 | 29 | |||
| Ki-67 expression (n = 95) | .009 | |||||||
| Positive | 83 | 46 | 55 | 37 | 45 | |||
| Negative | 12 | 2 | 17 | 10 | 83 | |||
LDH categorization is based on the range for normal values in the clinical laboratory at our institution. LDH levels were missing in 2 patients but both patients had a total IPI score of 4 and were categorized in the high-risk group.